The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer.本発明は、腫瘍療法に関する。一態様では、本発明は、がんの治療において有用な標的結合部分及び毒素の複合体に関する。特に、毒素はアマトキシンであり、標的結合部分(例えば抗体)は腫瘍関連抗原、例えば上皮細胞接着分子(EpCAM)に指向性を有する。さらなる一態様では、本発明は、かかる標的結合部分毒素複合体を含む医薬組成物に、及びかかる医薬組成物の調製のためのかかる標的結合部分毒素複合体の使用に関する。本発明の標的結合部分毒素複合体及び医薬組成物は、がん、特に腺癌、例えば膵臓がん、胆管癌、乳がん及び結腸直腸がんの治療に有用である。【選択図】図1
